Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $215

Benzinga Newsdesk www.benzinga.com Positive 86.3%

Neg 0% Neu 0% Pos 86.3%

Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $188 to $215.